SCHEMBL3089520

SCHEMBL3089520

O=C1c2ccccc2CC1(c1ccccc1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
LMNA P02545 1/20 0.51
HTT P42858 1/20 0.51
CFTR P13569 1/20 0.40
GOPC Q9HD26 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAOA P21397 2/20 0.39
CYP2A6 P11509 1/20 0.39
MAOB P27338 1/20 0.39
CES1 P23141 1/20 0.39
POLB P06746 2/20 0.39
ALDH1A1 P00352 1/20 0.39
PKM P14618 1/20 0.38
KMT2A Q03164 1/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2920984 0.85 MAPT (0.43) NPSR1L3MBTL1LMNAHTTGAA
SCHEMBL28357232 0.80 MAPT (0.44) NPSR1L3MBTL1LMNAHTTCFTR
SCHEMBL14938940 0.77 NPSR1 (0.49) NPSR1L3MBTL1LMNAHTTCFTR
SCHEMBL9641039 0.77 LMNA (0.49) NPSR1L3MBTL1LMNAHTTCFTR
SCHEMBL31722857 0.72 PDK2 (0.43) NPSR1L3MBTL1LMNAHTTGAA
SCHEMBL3134200 0.72 NPSR1 (0.44) NPSR1L3MBTL1LMNAHTTCFTR
SCHEMBL4459204 0.71 NPSR1 (0.50) NPSR1L3MBTL1LMNAHTTMAOA
SCHEMBL3994729 0.71 L3MBTL1 (0.50) NPSR1L3MBTL1LMNAHTTMAOA
SCHEMBL11500029 0.71 SIGMAR1 (0.51) NPSR1L3MBTL1LMNAHTTMAOA
SCHEMBL4463201 0.71 NPSR1 (0.50) NPSR1L3MBTL1LMNAHTTMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114890881-B Method for simply synthesizing allyl dicarbonyl compound 南阳师范学院 2023-06-02 CN disclosed
US-20220047557-A1 TREATMENT OF CARDIAC DISORDERS BY BLOCKING SK4 POTASSIUM CHANNEL RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2022-02-17 US disclosed
US-11166940-B2 Treatment of cardiac disorders by blocking SK4 potassium channel RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2021-11-09 US disclosed
CN-108697081-B Molecules having pesticidal utility, and intermediates, compositions and methods related thereto 美国陶氏益农公司 2021-07-23 CN disclosed
US-20180177764-A1 TREATMENT OF CARDIAC DISORDERS BY BLOCKING SK4 POTASSIUM CHANNEL RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2018-06-28 US disclosed
US-9691999-B2 Photoelectric conversion device vapor deposition material, photoelectric conversion device, sensor, and imaging device FUJIFILM CORPORATION (JP) 2017-06-27 US disclosed
US-20140138522-A1 PHOTOELECTRIC CONVERSION DEVICE VAPOR DEPOSITION MATERIAL, PHOTOELECTRIC CONVERSION DEVICE, SENSOR, AND IMAGING DEVICE FUJIFILM CORPORATION (JP) 2014-05-22 US disclosed
WO-2013015441-A1 PHOTOELECTRIC CONVERSION DEVICE VAPOR DEPOSITION MATERIAL, PHOTOELECTRIC CONVERSION DEVICE, SENSOR, AND IMAGE PICKUP DEVICE FUJIFILM CORPORATION (JP) 2013-01-31 WO disclosed
WO-2010109008-A1 PRODRUGS OF SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONES TOPOTARGET A/S (DK) 2010-09-30 WO disclosed
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TOPOTARGET A/S (DK) 2010-09-09 US disclosed
US-7342038-B2 Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation PRESIDENT AND FELLOW OF HARVARD COLLEGE (US) 2008-03-11 US disclosed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
CN-1688288-A Preparation of submicron sized particles with polymorph control and new polymorph of itraconazole BAXTER INT (US) 2005-10-26 CN disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed
US-20040242563-A1 Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation CHILDREN'S MEDICAL CENTER CORPORATION 2004-12-02 US disclosed
US-6800658-B2 A POTENT AND SAFE INHIBITORS OF MAMMALIAN CELL PROLIFERATION FOR TREATING OR PREVENTING CANCER, BLOOD VESSEL PROLIFERATIVE DISORDERS, FIBROTIC DISORDERS AND ARTERIOSCLEROTIC CONDITIONS CHILDREN'S MEDICAL CENTER CORPORATION 2004-10-05 US disclosed
US-20020198188-A1 Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation CHILDREN'S MEDICAL CENTER CORPORATION 2002-12-26 US disclosed
US-20020128256-A1 Methods for the treatment or prevention of inflammatory diseases characterized by abnormal cell proliferation BRUGNARA CARLO (US) 2002-09-12 US disclosed
CN-1306422-A Substituted diphenyl indanone, indane and indole compounds and analogs thereof for the treatment or prevention of diseases characterized by abnormal cell proliferation HARVARD COLLEGE (US) 2001-08-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128256-A1 Methods for the treatment or prevention of inflammatory diseases characterized by abnormal cell proliferation KCNN3, KCNN2, KCNN1 NPSR1 3140/4885L3MBTL1 3719/4885LMNA 1063/4885
US-11166940-B2 Treatment of cardiac disorders by blocking SK4 potassium channel KCNN3, KCNK4, KCNN1 NPSR1 911/4885L3MBTL1 923/4885LMNA 1661/4885
US-20220047557-A1 TREATMENT OF CARDIAC DISORDERS BY BLOCKING SK4 POTASSIUM CHANNEL KCNN3, KCNK4, KCNN1 NPSR1 911/4885L3MBTL1 923/4885LMNA 1661/4885
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 NPSR1 3513/4885L3MBTL1 464/4885LMNA 3104/4885
US-20040242563-A1 Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation IDO1, ING2, MKI67 NPSR1 2537/4885L3MBTL1 742/4885LMNA 2365/4885
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TPH2, TPH1, HTR2C NPSR1 1252/4885L3MBTL1 2191/4885LMNA 2104/4885
US-20020198188-A1 Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation IDO1, IDO2, ING2 NPSR1 2482/4885L3MBTL1 714/4885LMNA 2296/4885
US-20180177764-A1 TREATMENT OF CARDIAC DISORDERS BY BLOCKING SK4 POTASSIUM CHANNEL KCNN3, KCNK4, KCNN1 NPSR1 911/4885L3MBTL1 923/4885LMNA 1661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.